Search Results
Sep 08, 2026, 08:00 ET Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) casesStrong clinical evidence demonstrates the device's high rates of safety and effectiveness in treating AFib patientsFDA approval of TactiFlex Duo strengthens Abbott's expanding PFA portfolio
More news about: Abbott
Aug 27, 2026, 09:00 ET Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
heart. It is the most common place for blood clots to form and can potentially lead to stroke for people with AFib, an irregular heartbeat in the heart's upper chambers. For patients with AFib who are unable to take blood-thinning medication long-term, physicians may opt for closure of the LAA through
More news about: Abbott
Jul 27, 2026, 23:00 ET New report identifies opportunities to help more patients in Asia Pacific benefit from advances in AFib care
half of eligible patients with AFib are referred for ablation within one year of diagnosis, highlighting the need for stronger education, care coordination and system readiness to help patients access advanced heart rhythm control therapies such as PFA sooner.AFib is becoming a growing healthcare
More news about: Boston Scientific
Jul 15, 2026, 07:00 ET Withings BodyScan 2 Now Available in the US, Setting a Standard in Preventive Health and Longevity Monitoring
purposes.2The 6-lead ECG and atrial fibrillation (AFib) detection features are medically regulated. These features are enabled in BodyScan 2 by Withings Scan Monitor 2.0, the FDA-cleared software (510(k) K230812) that powers ECG and AFib detection on the device — the clearance applies to this
More news about: Withings
Jun 18, 2026, 09:10 ET AHN's Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
institutions in the country to introduce an innovative ablation technique known as pulsed field ablation (PFA) for the treatment of atrial fibrillation (AFib).
More news about: Allegheny Health Network
Jun 15, 2026, 19:01 ET The AI from Skin Analytics that caught 20,000 cancers in the UK is now certified for use on a standard smartphone
new models of care with partners across Europe. This is the turning point when a skin cancer assessment will become as everyday as getting an ECG for AFib detection on a smartwatch. We see a world where no one dies of skin cancer, and this is how we get there."Dr Alexandra Kemp, Consultant Dermatologist
More news about: Skin Analytics
Jun 03, 2026, 06:55 ET Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures for cardiac arrhythmias such as atrial fibrillation (Afib). Medtronic intends to integrate ICE into the Affera™ mapping and ablation system to continue building on the differentiated value proposition of the
More news about: Medtronic plc
May 19, 2026, 13:21 ET Ascent Strategy Group Named One of the Best Healthcare PR Agencies in the World
PR Week Healthcare Awards for one of the best healthtech campaigns of the year for the launch of the first blood pressure monitor with AI-powered AFib detection.
More news about: Ascent Strategy Group
May 11, 2026, 07:04 ET Biozen Receives FDA Clearance for Calibration-Free Cuffless Blood Pressure Technology
photoplethysmogram and pressure signals obtained from the index finger.User Population: Adults ages 22-59 who do not have active arrhythmias (e.g. Afib), peripheral artery disease, or are pregnant.Environment of Use: HomeMedia Contact Ashley Wilson
More news about: Biozen, LLC
May 07, 2026, 02:00 ET Withings Analysis of 470,000 US Women Reveals AFib Prevalence Increases 3.8x and HRV Declines During Menopause
earlier intervention." - Aline Criton, Chief Regulatory and Clinical Affairs Officer, WithingsThe AFib Signal: A 3.8x Rise Across the Transition Atrial fibrillation (AFib), an irregular heart rhythm linked to stroke and heart failure, follows a steep, accelerating curve across the
More news about: Withings
Apr 25, 2026, 12:30 ET Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib casesNew data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablationTwo new conduction system
More news about: Abbott
Apr 25, 2026, 12:30 ET Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues
data presented at the Heart Rhythm Society (HRS) Annual Meeting and the start of a new trial to evaluate a broader population of atrial fibrillation (AFib) patients. With ongoing positive physician feedback and global commercial expansion, Medtronic continues to invest in clinical research to study the
More news about: Medtronic plc
Apr 16, 2026, 07:30 ET Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin
More news about: Abbott
Mar 28, 2026, 10:55 ET CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Feb. 3, 2026.2 FAQ About AFib. American Heart Association, Inc., 2023.
More news about: Boston Scientific Corporation
Mar 23, 2026, 08:33 ET Korea University Study Identifies Liver-Metabolic Disease as a Key Risk Factor for Heart Failure in Older Adults with Atrial Fibrillation
indicates that these SLD subtypes are closely linked to the development and progression of both AFib and HF. However, the complex interplay between cardiac, hepatic, and metabolic vulnerabilities in the context of AFib stratified by SLD subtype remains poorly understood. A team of researchers from Korea
More news about: Korea University College of Medicine
Mar 22, 2026, 22:24 ET 雲頂新耀與箕星藥業達成資產收購協議 將在大中華區開發及商業化艾曲帕米鼻噴霧劑
SVT患者提供全新的治療選擇。PSVT是一種以突發突止為主要特徵的心動過速臨床綜合征，發作時心率極快且節律規則，通常持續數分鐘至數小時，患者症狀明顯且恐懼感強。PSVT急性發作的治療缺乏安全、便捷、可在院外自行使用的快速終止藥物，使患者在發作期長期處於「被動等待」狀態，缺乏真正意義上的「按需自救」工具。在中國，每1000中約有2.3-4人患有PSVT，估計總患者人數為300-600萬。AFib-RVR的特徵是心率不規則，紊亂且快速，呈漸進式發作且不易自行終止，容易反覆持續。目前中國的房顫患病率1.6%，對應患者人數約2000萬，並隨老齡化加劇呈上升趨勢。PSVT與AFib-RVR都會增加患者的失控感和心理負擔。在
More news about: 雲頂新耀
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib), during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved
More news about: Market News Updates
Feb 06, 2026, 08:00 ET Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
recurrence among all competitive PFA products to treat AFib episodes that come and go (Paroxysmal AFib or PAF).1Volt also delivered strong results as a treatment option for AFib episodes that last longer than seven days (Persistent AFib or PersAF), with nearly 68% of patients remaining free
More news about: Abbott
Feb 03, 2026, 09:05 ET Nation's First Cardiac Arrhythmia-Focused Healthcare Network Launches with New Mexico's First ASC-Based Ablation Procedures
Current Clinic launches specialized care model for AFib patients; completes inaugural cardiac ablation procedures in Carlsbad ambulatory surgery centerCARLSBAD, N.M., Feb. 3, 2026 /PRNewswire/ -- Current Clinic
More news about: Current Clinic Management LLC
Jan 23, 2026, 07:02 ET Affera™ momentum continues as Medtronic announces CE Mark in Europe and U.S. IDE first cases for Sphere-360™ PFA catheter to treat paroxysmal atrial fibrillation
Medtronic.com.About Atrial FibrillationAFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide1. AFib is a progressive disease, often beginning as paroxysmal AFib (presents intermittently) and progressing to persistent
More news about: Medtronic plc
Jan 21, 2026, 13:04 ET LifeQuotes.com Celebrates 146,000 Direct Customer Reviews Averaging 4.7 Stars; 3,000 Google Reviews Averaging 4.8 Stars; Announces Expansion of Instant Decision, No-Exam Life Insurance up to $10 Million
those who take Prescription DrugsLifequotes.com specializes in advising customers who have chronic medical conditions such as: Abnormal EKG, AFIB (Arterial Fibrillation), Alcohol Abuse, Alzheimer's, Anxiety (including ADD or ADHD), Artery (Coronary) Disease, Arthritis (Psoriatic or Rheumatoid),
More news about: Life Quotes, Inc.
Jan 20, 2026, 09:00 ET Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
the safety and effectiveness of treating patients with AFib1.Approximately eight million Europeans over the age of 65 are living with AFib, a number expected to double over the next 30 years2,3. People living with AFib face an increased risk of stroke, heart failure and death,
More news about: Abbott
Jan 07, 2026, 06:00 ET Precision Redefined: LUMA Vision Completes VERAFEYE™ 4D-Guided Persistent AF Ablations, Demonstrating a Significant Advancement in Simplifying Image-Guided Cardiac Care
anatomical modelling with automatic catheter tracking and guidance, VERAFEYE is redefining how ablation procedures for both paroxysmal and persistent AFib are planned, executed, and verified — setting a new standard for efficiency and accuracy in the new era of PFA."Using an empirical lesion set
More news about: LUMA Vision
Jan 07, 2026, 06:00 ET Precision Redefined: LUMA Vision Completes VERAFEYE™ 4D-Guided Persistent AF Ablations, Demonstrating a Significant Advancement in Simplifying Image-Guided Cardiac Care
anatomical modelling with automatic catheter tracking and guidance, VERAFEYE is redefining how ablation procedures for both paroxysmal and persistent AFib are planned, executed, and verified — setting a new standard for efficiency and accuracy in the new era of PFA."Using an empirical lesion set
More news about: LUMA Vision
Jan 06, 2026, 06:50 ET W. L. GORE & ASSOCIATES ÜBERNIMMT CONFORMAL MEDICAL UND BAUT SEINE PRÄSENZ IM BEREICH DER ENDOVASKULÄREN BEHANDLUNGEN AUS
Vorhofflimmern (AFib), der darauf abzielt, das Risiko der Bildung von Schlaganfall verursachenden Blutgerinnseln im LAA zu verringern und die Notwendigkeit einer langfristigen täglichen oralen Antikoagulanzientherapie zu beseitigen. Laut der American Heart Association wird die Zahl der AFib-Fälle in den
More news about: W. L. GORE & ASSOCIATES